SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.51+2.7%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (2249)12/7/2000 1:49:52 PM
From: Biomaven  Read Replies (1) of 52153
 
tom,

isn't the net effect the ex post facto capitalization of R&D?

Yes, but as I mentioned and Nigel re-iterated, here there's an arm's length transaction that demonstrates that the R&D has value at the time of the merger. Thus this is a less extreme position than recognizing that R&D spending produces an asset in the first place.

Key though is that the accountants are finally moving to a recognition that intangible assets are not necessarily decaying assets.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News